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Abstract
Background: The purpose of this study is to review our results for pancreatic resection in patients with intraductal
papillary mucinous neoplasm (IPMN) with and without associated carcinoma.
Methods: A total of 54 patients undergoing pancreatic resection for IPMN in a single university surgical center
(Medical University of Graz) were reviewed retrospectively. Their survival rates were compared to those of patients
with pancreatic ductal adenocarcinoma.
Results: Twenty-four patients exhibit non-invasive IPMN and thirty patients invasive IPMN with associated carcinoma. The
mean age is 67 (+/-11) years, 43 % female. Surgical strategies include classical or pylorus-preserving Whipple procedure
(n = 30), distal (n = 13) or total pancreatectomy (n = 11), and additional portal venous resection in three patients (n= 3).
Median intensive care stay is three days (range 1 – 87), median in hospital stay is 23 days (range 7 – 87). Thirty-day
mortality is 3.7 %. Median follow up is 42 months (range 0 – 127). One-, five- and ten-year overall actuarial survival is 87 %;
84 % and 51 % respectively. Median overall survival is 120 months. Patients with non-invasive IPMN have significantly
better survival than patients with invasive IPMN and IPMN-associated carcinoma (p < 0.008). In the subgroup of invasive
IPMN with associated carcinoma, a positive nodal state, perineural invasion as well as lymphovascular infiltration are
associated with poor outcome (p < 0.0001; <0.0001 and =0.001, respectively). Elevated CA 19-9(>37 U/l) as well as
elevated lipase (>60 U/l) serum levels are associated with unfavorable outcome (p = 0.009 and 0.018; respectively).
Patients operated for pancreatic ductal adenocarcinoma show significantly shorter long-term survival than patients with
IPMN associated carcinoma (p = 0.001).
Conclusions: Long-term outcome after pancreatic resection for non-invasive IPMN is excellent. Outcome after resection
for invasive IPMN with invasive carcinoma is significantly better than for pancreatic ductal adenocarcinoma. In low- and
intermediate risk IPMN with no clear indication for immediate surgical resection, a watchful waiting strategy should be
evaluated carefully against surgical treatment individually for each patient.
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Background
The intraductal papillary mucinous neoplasm (IPMN) is
the most frequent cystic lesion of the pancreas, originat-
ing from the epithelial cells of the pancreatic duct or its
branches. IPMN produce mucin and leads to typical
dilatation of pancreatic ducts [1]. In 1996, the entity of
IPMN was included in the World Health Organization
(WHO) classification of pancreatic neoplasms [2]. The
histopathological diagnosis of IPMN requires the presence
of neoplastic epithelium with intraductal proliferation of
columnar mucinous cells, generally with papillary archi-
tecture [1, 3]. IPMNs as well as other cystic pancreatic tu-
mors are increasingly diagnosed, mostly due to the greater
diagnostic accuracy of radiologic imaging modalities such
as multi-detector row computed tomography (MDCT)
and magnetic resonance imaging (MRI) and better aware-
ness on the part of pathologists of this entity. Frequently,
a cystic pancreatic lesion is diagnosed incidentally in
asymptomatic patients undergoing abdominal diagnostics
for other potential pathologies [4].
IPMNs are classified according to their radiologic and
macroscopic morphologic features into a main duct (MD-
IPMN; from 16 – 36 %), a branch duct (BD-IPMN; from
40 – 65 %) and a mixed type (15 – 23 %). The rate of inva-
sive IPMN is significantly higher in main and mixed type
lesion than in branch duct IPMN [5, 6]. The malignant
potential of IPMN is based on an adenoma-carcinoma
sequence [6, 7], which is not the case for ductal adenocar-
cinoma of the pancreas, where the sequence from low
grade to high grade pancreatic intraepithelial neoplasia
(PanIN) and further to ductal adenocarcinoma is well
established [8]. IPMNs are further classified according to
the degree of dysplasia as low, intermediate and high
grade dysplasia as well as IPMN with associated carcin-
oma, previously described as adenoma, borderline and
carcinoma in situ and invasive carcinoma lesions [9,
10]. Histopathological and immune-histochemical ana-
lysis differentiates between four subtypes: the intestinal,
the gastric, the oncocytic and the pancreato-biliary type
[11–14]. An IPMN can occur with associated adenocar-
cinoma as well as concomitant adenocarcinoma, the
latter with lower long-term survival [15, 16].
The localization of an IPMN can be uni- or multifocal,
and determines the type of surgical resection [2, 6, 7].
The treatment modalities of IPMN were described in the
Fukuoka guidelines: patients with main or mixed duct
IPMN should be always scheduled for surgical resection.
Branch duct lesions with „worrisome features“(cystic size >
30 mm, thickened cystic walls, non-enhanced mural le-
sions, dilatation of the pancreatic duct of 5 – 9 mm,
lymphadenopathy, distal pancreatic atrophy, caliber
alterations of the pancreatic duct) or “high-risk stig-
mata” (duct dilatation > 5 mm, solid enhancing compo-
nents with biliary obstruction) should be considered
for surgical resection. Clinically symptomatic lesions
always require surgical intervention [7].
This study reports our experience with pancreatic re-




Fifty-four consecutive patients (43 % female; mean
age 67 +/- 11 years) who in a 13-year period under-
went pancreatic resection for IPMN with or without asso-
ciated carcinoma at our institution were reviewed
retrospectively. Patients with infiltration of portal venous
branches requiring vascular resection and subsequent re-
construction were included. Survival rates were compared
to a total of 221 patients operated for pancreatic ductal
adenocarcinoma during the same period at our institution.
The institutional review board approved the study and
waived the need for patient consent according to the
Helsinki and its own criteria [EK 25 -404 - ex 12/12].
Preoperative diagnostic algorithm
All patients underwent a detailed clinical examination,
blood testing including functional liver parameters as
well as tumor markers carcino-embryonic antigen
(CEA) and carbohydrate antigen (CA) 19-9. Preopera-
tive radiologic imaging included abdominal ultrasound,
MDCT with pancreas protocol and/or MRI with
cholangio-pancreaticography (MRCP) and/or endo-
scopic retrograde cholangiopancreatography (ERCP).
Computed-tomography (CT) guided biopsy was per-
formed for further investigation of unclear cystic
lesions of the pancreas; it should be noted that during
the study period, the newer methods of endoscopic
ultrasound (EUS) and fine needle aspiration (FNA) saw
increasing clinical application. Positron emission tom-
ography (PET) scan was performed for oncological
staging.
Surgical approach
The type of resection was based on tumor localization: pa-
tients presenting with lesions of the pancreatic head or
processus uncinatus received standard or pylorus preserv-
ing pancreatico-duodenectomy; those with lesions in the
pancreatic tail and/or body received distal pancreatectomy
with splenectomy in patients with invasive lesions, and
spleen-preserving surgery when the intraoperative rapid
frozen section showed no invasive component. Total pan-
createctomy was conducted in patients with diffuse distri-
bution of IPMN and/or large tumor size involving the
pancreatic head and body. The bilio-digestive anastomoses
were connected with 5-0 or 6-0 double layer single su-
tures. Internal drains placed routinely to protect the
pancreatico-jejunostomy and the hepatico-jejunostomy,
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which were both performed as end-to-side anastomosis.
The standard protocol called for intraoperative rapid
frozen section diagnosis and depending on that histopath-
ologic diagnosis, resection was extended until negative
margins could be obtained when there was high-grade
dysplasia, invasive IPMN and/or high-grade PANin. If this
was not possible, the surgical strategy was changed to total
pancreatectomy.
Follow-up protocol
Postoperative complications were classified according to
the system established by Clavien and Dindo [17]. All
patients underwent clinical, laboratory and radiological
follow-up three, six and twelve months postoperatively,
and every six months thereafter. Follow-up data were
obtained from the patient’s records, the hospital data-
base and the national cancer registry [Austrian National
Cancer Registry; [18]].
Statistical analysis
Data were acquired prospectively and saved an institutional
pancreatic database including baseline data, pre-, intra- and
postoperative parameters, results of histopathological and
immune-histochemical assays and follow-up details.
Data were collected retrospectively in an Excel data-
base (Microsoft Inc., Redmond, USA) All statistical ana-
lyses were performed with SPSS 22.0 for Windows (IBM
Inc., Somers, USA). If not otherwise indicated, continu-
ous variables were reported as mean and standard devi-
ation; categorical data were reported as count and
percentages. Categorical variables were compared with
Fisher’s exact or the Chi-square test, as appropriate; for
numeric variables, we used the Wilcoxon test. A p < 0.05
was considered statistically significant. Overall survival
was calculated according the method of Kaplan and
Meier. Differences between subgroups were compared
with the log-rank test.
Results
Preoperative results
Mean age is 67 ± 11 (range 29 – 84) years, 43 % female,
mean body mass index was 25 ± 4. At initial presenta-
tion, seventy-eight percent of patients are symptomatic;
only 22 % are asymptomatic and diagnosed incidentally
with cystic pancreatic mass after undergoing abdominal
imaging for other reasons. Seven percent of patients
have jaundice with a serum bilirubin value greater than
3 mg/dl. The distribution of baseline and preoperative
patient’s characteristics in both non-invasive and inva-
sive subgroups is presented in Table 1. Initial diagnostic
imaging always includes abdominal sonography; further,
there is MDCT with pancreas protocol in 91 % and ab-
dominal MRI in 69 %. For detailed evaluation of the
pancreatic duct system, we perform an ERCP in 39 %
and MRCP in 35 %. A malignant lesion is suspected in
20 % and staging diagnostics are completed with a PET
scan; CT-guided biopsy is performed in 19 %. In
preoperative radiological diagnostic imaging, a cystic
diameter > 3 cm is present in 38 % of patients with
non-invasive and 47 % of patients with invasive IPMN
(p = 0.50). Preoperative liver function parameters are
displayed in detail in Tables 2 and 3.
Operative results
Pancreatic resection is performed as a classical Kausch-
Whipple procedure in 15 %, pylorus preserving pancrea-
ticoduodendectomy in 41 % of patients. Twenty-four
percent % of patients are treated with distal and 20 % of
patients with total pancreatectomy. Splenectomy is per-
formed in 35 % of patients. The distribution of surgical
approaches between invasive and non-invasive subgroups
is shown in Table 4. Three patients with portal venous in-
filtration require a more radical surgical approach includ-
ing an extended resection of mesenterico-portal venous
tissue. After resection, the portal axis is reconstructed by
interposition of a Gore-Tex® tube graft using a running
polypropylene suture. The mean duration of surgery is
293 (range 115 – 525) minutes; fifty percent of patients
require intraoperative blood products.
Postoperative results
The median hospital stay is 23 (range 7 – 87) days, and
the median ICU (intensive care unit) stay 3 (range 1 – 87)
days. Twenty-six percent of all patients, 25 % of patients
in the non-invasive as well as 27 % in the invasive sub-
group receive transfusion of red blood cells during the
postoperative period (p = 0.92). Sixty-three percent of pa-
tients show an uneventful postoperative course. Postoper-
ative morbidity details for the other patients are displayed
in detail in Table 5. Thirty-day mortality is 3.7 % (2 out of
54 pts), both with an invasive IPMN with associated
carcinoma. Nineteen percent of patients, all of whom hav-
ing an IPMN associated carcinoma, receive postoperative
chemotherapy; none of patients undergoes radiotherapy.
Histopathological results
In 44 % of pts, definitive postoperative histopathological
examination reveals a non-invasive IPMN. The remaining
56 % suffer from IPMN with associated carcinoma, i.e., in-
vasive IPMN. Seven percent are classified as MD-, 17 % as
BD- and 32 % as mixed type IPMN. In the remaining
44 % of patients, no further specification is undertaken.
Immuno-histochemical analysis demonstrates gastral sub-
type in 15 %, intestinal in 17 %, pancreato-biliary in 6 %
and mixed type in 11 %; in 52 %, no immuno-
histochemical data are available. Details of histopathologic
tumor size and localization are shown in Table 6.
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Table 1 Demographic and preoperative patient data
Factor Overall (n = 54) Non-invasive IPMNa (n = 24) Invasive IPMNa (n = 30) Two-sided p-value
Age (years) 67 ± 11 66 ± 12 67 ± 11 0.70
Age > 70 years 23 (43 %) 9 (38 %) 14 (47 %) 0.50
Female gender 31 (57 %) 14 (58 %) 17 (57 %) 0.90
Body mass index 25 ± 4 26 ± 4 25 ± 4 0.51
American Society of Anesthesiologists (ASA) classification
ASA I 3 (6 %) 3 (13 %) 0 0.06
ASA II 19 (35 %) 8 (33 %) 11 (37 %) 0.86
ASA III 25 (46 %) 11 (46 %) 14 (47 %) 1.00
ASA IV 7 (13 %) 2 (8 %) 5 (17 %) 0.42
Chronic health factors
Smoking 18 (33 %) 8 (33 %) 10 (33 %) 1.00
Alcoholism 7 (13 %) 2 (8 %) 5 (17 %) 0.37
Preoperative symptoms
Abdominal pain 36 (67 %) 15 (63 %) 21 (79 %) 0.57
Nausea 7 (13 %) 1 (4 %) 6 (20 %) 0.09
Diarrhea 3 (6 %) 1 (4 %) 2 (7 %) 0.69
Weight loss 15 (28 %) 5 (21 %) 10 (33 %) 0.32
Diabetes 27 (50 %) 7 (29 %) 20 (77 %) 0.006
Jaundice 4 (7 %) 1 (4 %) 3 (10 %) 0.42
Comorbidities
Arterial hypertension 31 (57 %) 14 (58 %) 15 (50 %) 0.91
Coronary artery disease 8 (15 %) 4 (17 %) 4 (13 %) 0.73
Chronic obstructive pulmonary disease 4 (7 %) 2 (8 %) 2 (7 %) 0.82
Gastroesophageal reflux disease 9 (17 %) 2 (8 %) 7 (23 %) 0.14
Gastritis 2 (4 %) 1 (4 %) 1 (3 %) 0.87
Hiatus hernia 6 (11 %) 2 (8 %) 4 (13 %) 0.56
Extra-pancreatic malignancy (current/anamnestic) 14 (26 %) 6 (25 %) 8 (27 %) 0.89
aIPMN intraductal papillary mucinous neoplasm
Table 2 Preoperative laboratory tests
Laboratory parameter Overall cohort






Alanin-Aminotransferase (ALT) (Units/liter (U/l)) 45.0 ± 63.9 39.6 ± 67.5 49.5 ± 61.5 0.16
Aspartat-Aminotransferase (AST)(U/l) 34.8 ± 29.1 33.4 ± 32.6 36 ± 26.5 0.34
Cholinesterase (CHE)(U/l) 6566.8 ± 2101.9 6409.7 ± 2230.9 6701.4 ± 2016.1 0.58
Alcalic phosphatase (ALP)(U/l) 126 ± 136.1 78.6 ± 9.5 166.3 ± 174.7 0.02
Gamma glutamyl transferase (GGT)(U/l) 126.9 ± 194.6 69.8 ± 154.3 174.1 ± 194.6 0.009
Carcinoembryonic antigen (CEA) (nanogramm/liter (ng/l)) 3.1 ± 2.8 2.6 ± 2.8 3.8 ± 2.7 0.07
Carbohydrate antigen (CA) 19-9 (U/l) 202.7 ± 734.0 20.3 ± 31.6 352.4 ± 972.2 0.001
Lipase (U/l) 80.1 ± 209.9 106.2 ± 311.6 59.1 ± 50.0 0.59
Amylase (U/l) 41.7 ± 80.7 55.2 ± 116.0 30.8 ± 31.0 0.19
Bilirubin (milligramm/deciliter (mg/dl)) 1.2 ± 2.8 1.1 ± 1.8 1.3 ± 3.4 0.63
aSD standard deviation
bIPMN intraductal papillary mucinous neoplasm
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Results at follow-up
Median follow-up is 42 (range 0 – 142) months. Eighty per-
cent of patients (43 out of 54) show no evidence of disease
and eleven percent are alive with disease, while the
remaining seventeen percent (9 out of 54) have succumbed
to their disease, all but one with a recurrence of invasive
IPMN and/or IPMN with associated carcinoma [Table 7].
One- and five-year overall actuarial survival is 87 and
84 % for the overall cohort [Fig. 1], for non-invasive
IPMN 100 % and 100 %, and for invasive IPMN 76 %
and 69 %, respectively [Fig. 2]. Median overall survival is
120 months for the overall cohort; 120 months for
patients with a non-invasive form and 111 months for
patients with invasive IPMN. In patients with invasive
IPMN, a positive nodal state, perineural invasion and
lymphovascular infiltration (p < 0.0001 vs. p < 0.0001 vs.
p = 0.001) are associated with unfavorable outcome; me-
dian overall survival in the absence of nodal disease was
120 months vs. 11.5 when IPMN is associated with
nodal disease. With perineural invasion, median overall
survival is 11 months vs. 120 months in the absence of
same. Lymphovascular invasion is associated with a
median overall survival of 11 months vs. 120 months
without lymphovascular infiltration [Figs. 3, 4 and 5].
Preoperatively elevated CA 19-9 serum levels (>37 U/l)
as well as elevated lipase levels (>60 U/l) are associ-
ated with unfavorable long term outcome (p = 0.009
vs p = 0.018, respectively) [Figs. 6 and 7].
Overall survival of IPMN associated carcinoma is cor-
related with survival of patients operated for ductal
adenocarcinoma [Fig. 8], with a significantly better long-
term outcome in patients undergoing pancreatic resec-
tion for IPMN associated carcinoma than for patients
suffering from ductal adenocarcinoma. The median
overall survival for patients with IPMN associated car-
cinoma is 60 months vs. 20 months for patients with
ductal adenocarcinoma. There is an actuarial one- and
five-year overall survival of 76 % and 52 % in patients
with IPMN associated carcinoma vs. 67 % and 8 % in pa-
tients with ductal adenocarcinoma (log rank: p = 0.001)
with no significant differences in baseline characteristics
such as age, gender and comorbidities [Table 8].
Discussion
The widespread use of imaging modalities such as
MDCT and MRI has increased the frequency of inciden-
tal detection of cystic pancreatic tumors, most com-
monly IPMN, in patients undergoing abdominal
diagnostic work-up for other diseases [19].
Table 3 Pathological preoperative laboratory values







Alanin-Aminotransferase (ALT) > 45 Units/liter
(U/l)
13 (25 %) 5 (21 %) 8 (28 %) 0.59
Aspartat-Aminotransferase (AST) > 35 U/l 14 (26 %) 6(25 %) 8 (28 %) 0.84
Cholinesterase (CHE) < 3900 U/l 10 (19 %) 5 (21 %) 5 (18 %) 0.79
Alcalic phosphatase (ALP) > 130 U/l 15 (30 %) 2 (8 %) 13 (48 %) 0.002
Gamma glutamyl transferase (GGT) > 55 U/l 22 (42 %) 8 (33 %) 14 (48 %) 0.28
Carcinoembryonic antigen (CEA) > 5 nanogramm/liter (ng/l) 9 (18 %) 3 (13 %) 6 (21 %) 0.45
Carbohydrate antigen (CA) 19-9 > 37 U/l 21 (41 %) 5 (22 %) 16 (57 %) 0.01
Lipase > 60 U/l 14 (26 %) 4 (17 %) 10 (33 %) 0.17
Amylase > 53 U/l 24 (44 %) 9 (38 %) 15 (50 %) 0.37
Bilirubin > 1.2 milligramm/deciliter (mg/dl) 11 (20 %) 6 (25 %) 5 (17 %) 0.46
aSD standard deviation
bIPMN intraductal papillary mucinous neoplasm
Table 4 Surgical measures
Surgical data Overall (n = 54) Non-invasive IPMNa (n = 24) Invasive IPMNa (n = 30) Two-sided p-value
Whipple procedure 8 (15 %) 5 (21 %) 3 (10 %) 0.27
Pylorus preserving pancreatico-duodenectomy 22 (41 %) 10 (42 %) 12 (40 %) 0.90
Distal pancreatectomy 13 (24 %) 6 (25 %) 7 (23 %) 0.89
Pancreatectomy 11 (20 %) 3 (13 %) 8 (27 %) 0.18
Vascular reconstruction 3 (6 %) 0 3 (10 %) 0.25
Intraoperative blood transfusion 27 (50 %) 10 (42 %) 17 (57 %) 0.52
aIPMN intraductal papillary mucinous neoplasm
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The distribution of age in our cohort is similar to
other surveys, with a wide range from 29 to 84 years
[14, 20, 21] and no preponderance of male or female
gender, as in other series [19, 22].
Most of our patients are symptomatic at initial pres-
entation, irrespective of the presence of an invasive
component. The distribution of symptoms do not differ
between the invasive and the non-invasive subgroup
apart from diabetes mellitus, and patients in the inva-
sive subgroup have a greater tendency toward nausea
(p = 0.09). As also reported by D’Angelica et al., in our
cohort, jaundice is not a common clinical presentation
in IPMN associated carcinoma patients, as only 7 %
have elevated serum bilirubin levels in contrast to 30 %
of patients with ductal adenocarcinoma and higher
serum bilirubin levels [15, 23].
New onset or preoperative aggravation of preexisting
diabetes mellitus is more frequent in the invasive sub-
group (p = 0.006), in agreement with Marchegiani et al.
[21]. In contrast to our series, they reported signifi-
cantly more patients presenting with preoperative ob-
structive jaundice and extensive weight loss when an
invasive IPMN was present. In their series, they further
differentiated between minimally invasive (<5 mm) and
macroscopically invasive (>5 mm) IPMN associated
carcinoma. They reported that both preoperative dia-
betes and obstructive jaundice were associated with
macroscopic invasive carcinoma, indicating that these
symptoms point to an aggressive tumor and/or locally
advanced disease [22].
In our series, 56 % of resected specimens include an in-
vasive component and/or an associated carcinoma, but
there is no concomitant ductal adenocarcinoma that did
not originate from premalignant intraductal lesions or
PanIN. This is reflected in a significantly better median
overall survival compared to median survival after resec-
tion for pancreatic ductal adenocarcinoma [23–25] as well
as significantly better 5-year overall survival [23, 26].
This can be explained by slower progression of the
malignant transformation into an invasive carcinoma.
Interestingly, in our series, bile duct obstruction is
only seen in the invasive group, with all the tumors
located in the pancreatic head. This finding is sup-
ported by Brambs et al. [27, 28] as well as Ogawa
et al. [29]; both judged biliary obstruction to be an
index for the malignancy of an IPMN lesion [20].
Table 5 Postoperative morbidity details
Morbidity details Overall (n = 54)
Cholangitis 1 (2 %)
Cholestasis 1 (2 %)
Postoperative shock 1 (2 %)
Fever of unknown origin 1 (2 %)
Anastomotic leakage 1 (2 %)
Bleeding 3 (6 %)
Pleural effusion 1 (2 %)
Abscess formation 3 (6 %)
Postoperative pneumonia 2 (4 %)
Pancreatic fistula 1 (2 %)
Multi organ failure 2 (4 %)
Atrial fibrillation 1 (2 %)
Table 6 Histopathological details
Histology Overall (n = 54) Non-invasive IPMNa (n = 24) Invasive IPMNa (n = 30) Two-sided p-value
Grade of dysplasia
Low grade 3 (6 %) 3 (13 %) 0 0.06
Intermediatea 11 (20) 11 (46 %) 0 <0.001
High grade 21 (29 %) 0 21 (70 %) <0.001
Mixed 19 (35 %) 10 (42 %) 9 (30 %) 0.54
Histopathological cyst size
<3 cm 24 (48 %) 11 (48 %) 13 (48 %) 0.91
>3 cm 26 (48 %) 12 (50 %) 14 (47 %) 0.81
Not available 4 (7 %) 1 (4 %) 3 (10 %) 0.47
R0 36 (67 %) 17 (71 %) 19 (63 %) 0.80
R1 18 (33 %) 7 (29 %) 11 (37 %) 0.68
Obstruction of the pancreatic duct 13 (24 %) 0 13 (43 %) 0.003
Concrements 2 (4 %) 0 2 (7 %) 0.21
Calcifications 8 (15 %) 3 (13 %) 5 (17 %) 0.71
Pancreatitis 30 (66 %) 14 (58 %) 16 (53 %) 0-85
aIPMN intraductal papillary mucinous neoplasm
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As reported above, none of patients suffers from a
concomitant ductal adenocarcinoma; but one-fourth of
them from a current and/or previous extra-pancreatic
malignancy. In four patients there is a history of renal
cell carcinoma, in one each, rectal carcinoma and
pulmonary carcinoma; other tumor entities included,
among others, ovarian, testicular or prostate cancer, and
a malignant tumor of the spine.
Sahora et al. reported a frequency of 7 % of concomitant
pancreatic ductal adenocarcinoma or peri-ampullary car-
cinoma in a recent series of 441 patients. It mainly occurred
in patients with branch duct IPMN; other synchronous
neoplasms in this series were found sporadically without
suspected association. This is in contrast to our data, in
which most of patients exhibit anamnestic extra-pancreatic
malignancy, corresponding to the life-time risk for malig-
nancies in an age adjusted population [30, 31].
Preoperative serum levels of CA 19-9 are significantly
higher in the invasive subgroup than in the non- invasive
subgroup in line with the findings of Kawai et al. and
Goh et al. [20, 32–35]. Nevertheless, the role of CA 19-9
as a predictor for invasiveness of an IPMN was seen
critically by other authors, above all for the sub-entity of
branch-duct IPMN. Sahora et al. reported that only 35 %
of pts with invasive BD-IPMN carcinoma showed elevated
CA 19-9 levels, while 14 % of patients with benign lesions
were false positive for CA 19-9 [36], indicating that CA
19-9 is not an appropriate diagnostic tool for preoperative
differentiation and decision making with respect to the
potential invasiveness of a cystic pancreatic mass, but can
be helpful together with cyst fluid analysis, cytopathology
and radiological imaging [7, 36]. In our series, we also ob-
serve significantly elevated levels of ALP (alkaline phos-
phatase) and GGT (gamma glutamyltransferase) in the
invasive subgroup. These laboratory values can be elevated
with other pathologies such as cystic pancreatic tumors or
pancreatic ductal adenocarcinoma, above all in inoperable
stages, and therefore do not predict invasiveness [37].
Preoperative diagnostics in our series includes MDCT
and/or MRI [20, 21, 36]. Additional ERCP is performed in
39 % and MRCP in 35 %; preoperative cytology from CT
guided biopsy is available for 19 % of patients. Follow-
ing implementation of the Fukuoka Guidelines, we in-
creasingly use EUS and fine needle aspiration [7]. EUS
Table 7 Follow-up details
Status at follow-up Overall (n = 54) Non-invasive IPMNa (n = 24) Invasive IPMNa (n = 30) Two-sided p-value
No evidence of disease 43 (80 %) 23 (96 %) 20 (71 %) 0.3
Dead of disease 9 (17 %) 1 (4 %) 8 (29 %) 0.05
Alive with disease 6 (11 %) 0 6 (20 %) 0.04
aIPMN intraductal papillary mucinous neoplasm
Fig. 1 Overall one- and five-year actuarial survival
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including Doppler ultrasound provided higher diagnostic
accuracy in preoperative evaluation of potential malig-
nancy of cystic pancreatic lesions thanks to better imaging
of the dilated pancreatic duct, and detailed imaging of the
morphology of an intraductal lesion [1, 38]. As a limita-
tion, there was significant inter-observer variability in the
diagnostic accuracy of EUS, depending on the experience
of the examiner. In experienced hands, together with PET,
MRCP and CT, the malignancy of an IPMN lesion could
be detected with a diagnostic accuracy of 90 % [39].
Perioperative morbidity and mortality in our series are
comparable to other studies [14, 21, 22, 35, 37, 40], with
no mortality in the non-invasive cohort [Table 9]. One-,
five- and ten-year overall survival rates are excellent for
the overall cohort but with a significantly poorer out-
come in the invasive subgroup, comparable to results
from other surveys [14, 22, 41]. For our non-invasive
subgroup, the 10-year overall survival rate is 80 %,
which is comparable to the age-adjusted attrition rate
[42]. In our cohort, the recurrence rate in the non-
invasive cohort is low, with one patient developing an
invasive recurrence and consecutively succumbs to his
disease during follow-up. All the other patients are
free of tumor recurrence at follow-up. Other series
reported recurrence rates up to 17 % for resected
non-invasive IPMN [36, 43, 44]. In our series, after
resection of invasive IPMN seventy-nine percent of
patients are free of tumor recurrence during follow-
up. In other series, the reported recurrence rate was
significantly higher, with 28 – 60 % after pancreatic
resection for invasive IPMN [20, 40, 45].
An invasive component, a positive nodal state, and lym-
phovascular and perineural invasion are associated with a
significantly poorer outcome in our study. Lymph node
positivity was also predictive for lower long-term survival
rates in other series [14, 22]. As is known for pancreatic
ductal adenocarcinoma, lympho-vascular as well as peri-
neural invasion were histological surrogates for advanced
disease and therefore associated with unfavorable long-
term outcome [25, 26, 45, 46].
The Fukuoka Guidelines offer a useful orientation on the
treatment of IPMN, but even with the high diagnostic
accuracy of radiologic imaging techniques, EUS, FNA,
cyto-pathological, immune-histochemical and genetic ana-
lyses, cystic pancreatic lesions cannot always be classified
correctly before resection. On the one hand, we have to be
aware of the potential danger that a cystic lesion classified
as low risk can progress to an invasive carcinoma over time.
Treatment options should be thoroughly discussed with
every patient with a cystic pancreatic mass and weighed
Fig. 2 Overall survival, non-invasive vs. invasive intraductal papillary mucinous neoplasm (IPMN)
Marsoner et al. BMC Cancer  (2016) 16:844 Page 8 of 14
Fig. 4 Overall survival according to lymphovascular invasion
Fig. 3 Overall survival according to nodal state
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Fig. 5 Overall survival according to perineural invasion
FIg. 6 Overall survival according to preoperative Carbohydrate
antigen (CA) 19-9 serum levels Fig. 7 Overall survival according to preoperativ lipase serum levels
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carefully against a watchful waiting strategy, particularly
with young, fit patients with low perioperative risk. On the
other hand, we are encouraged to follow the therapeutic al-
gorithm of the Fukuoka Guidelines [7] and avoid “unneces-
sary” pancreatic resections that could result in even higher
mortality that would then be IPMN-associated [19]. This is
of special impact for patients with diffuse distribution of
low-risk IPMN where curative resection is only accessible
by means of total pancreatectomy – we performed total
pancreatectomy in 13 % of patients with non-invasive
IPMN – with postoperative brittle diabetes and its associ-
ated risks and reduced quality of life as a consequence [22].
Limitations and strength of the study
This report has all the limitations of a retrospective single
center study. Because of the retrospective nature of this
Fig. 8 Overall survival, invasive intraductal papillary mucinous neoplasm (IPMN) vs. pancreatic ductal adenocarcinoma
Table 8 Baseline characteristics invasive intraductal papillary mucinous neoplasm (IPMN) vs. pancreatic ductal adenocarcinoma
Factor Invasive IPMNa (n = 30) Pancreatic ductal adenocarcinoma (n = 221) Two-sided p-value
Age (years) 67 ± 11 66 ± 9 0.58
Age > 70 years 14 (47 %) 75 (34 %) 0.17
Female gender 17 (57 %) 112 (51 %) 0.54
Body mass index 25 ± 4 26 ± 4 0.78
American Society of Anesthesiologists (ASA) classification
ASA I 0 8 (4 %) 0.29
ASA II 11 (37 %) 75 (35 %) 0.77
ASA III 14 (47 %) 113 (52 %) 0.65
ASA IV 5 (17 %) 20 (9 %) 0.19
aIPMN intraductal papillary mucinous neoplasm
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Salvia et al. [44] n = 140 47 (34 %) 83 (66 %) 0 33 (24 %)(major
complication)
10-year overall survival non-invasive IPMNa 100 %;
invasive IPMNa: 50 %.
n.s.b
Sohn et al. [14] n = 136 84 (62 %) 52 (38 %) 5 (3.7 %) 47 (35 %) 5-year overall survival non-invasive IPMNa :77 %;
invasive. IPMNa: 43 %.
n.s.b
D'Angelica et al. [15] n = 62 a 33a (52 %) 30 (48 %) 4 (6 %) 31 (50 %) 5-year-overall survival:75 %/10 year-overall
survival:60 %
23 % a 1 patient
Unresectable
Rodriguez et al. [39] n = 145 113 (78 %) 32 (22 %) 0 86 (59 %) 10-year-overall survival: 70 %, invasive Carcinoma :
10-year-overall survival: 63 %
6.9 % only branch
duct-IPMNa
Niedergethmann [20] n = 97 29 (30 %) 68 (70 %) 1 (1 %) 55 (56.7 %) median overall survival: 36 months n.s.b
Sahora et al. [35] n = 226 174 (77 %) 52 (23 %) 1.3 % 34 % n.s. 8.5 % only branch-duct-IPMNa
Marchegiani et al. [21] n = 173 48 (28 %) 125 (72 %) 0 15.6 % ("major surgical
complications")
10 year-overall survival: 69 % 25 % only main-duct-IPMNa
present series n = 54 24 (44 %) 30 (56 %) 2 (3.7 %) 20 (37 %) 5-year-overall survival non-invasive IPMNa:
100 %, invasive IPMNa 69 %
6 (12 %)













study over a 13-year period, numerous patients in this
series were not treated with strict adherence to the Fukuoka
guidelines. We cannot exclude that some patients in the
non-invasive subgroup were over-treated from the present
point of view. Our study deals with a patient population
suffering from what is still a challenging disease that
demands a “tailored approach“, taking into account both
the guidelines and the individual patient’s state of health.
This is indispensable if surgeons are to choose an optimal
medical treatment that would neither miss potentially inva-
sive IPMN nor over-treat, with subsequent surgery-related
morbidity and mortality.
Conclusion
Both long-term and disease-free survival after pancreatic
resection for non-invasive IPMN is excellent; survival
rates after pancreatic resection for invasive IPMN and
IPMN-associated carcinoma are significantly higher than
for patients undergoing resection for pancreatic ductal
adenocarcinoma. In low- and intermediate risk IPMN
with no clear indication for surgical intervention, a close
follow-up strategy according to the guidelines [7] should
be considered carefully and evaluated against surgical
treatment for every potential risk candidate risk by an
interdisciplinary board consisting of hepatobiliary sur-
geons, pathologists, radiologists and oncologists.
Abbreviations
ALP: Alcalic phosphatase; BD-IPMN: Branch-duct IPMN; CA 19-9: Carbohydrate
antigen; CEA: Carcino-embryonic antigen; CT: Computed tomography;
ERCP: Endoscopic retrograde cholangio-pancreaticography; EUS: Endoscopic
ultrasound; FNA: Fine needle aspiration; GGT: Gamma glutamyl transferase;
ICU: Intensive care unit; IPMN: Intraductal papillary mucinous neoplasm;
MDCT: Multi-detector computed tomography; MD-IPMN: Main-duct IPMN;
MRCP: Magnetic resonance cholangio-pancreaticography; MRI: Magnetic
resonance imaging; PanIN: Pancreatic intraepithelial neoplasia; PET: Positrone
emission tomography; WHO: World Health Organization
Acknowledgements
We thank Mrs. Eugenia Lamont (Department of Surgical Research, Medical
University of Graz, Austria) for proof-reading and language editing. All other
persons involved in this study meet criteria for authorship; none of authors
received financial support.
Funding
The authors did not receive any financial support or funding.
Availability of data and sources
The datasets supporting the conclusions of the article are included within
the article.
Authors’ contributions
KM, DC, JS, RL and JEW contributed to data acquisition and collection. KM,
JH, (these two authors contributed equally), DC and PK made substantial
contributions to the conception and design of the study. The manuscript
was drafted and critically revised by PK, JH and HJM. DC and KM contributed
to the statistical analysis. The study was supervised by PK. All authors read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interest.
Consent for publication
Informed consent was not obtained from the patients because this
retrospective study was approved by the local Ethical Committee, which
waived the requirement for written patients’ consent.
Ethics approval and consent to participate
This retrospective study was approved by the Ethics Committee of the
Medical University of Graz (EK 25 -404 - ex 12/12), which waived the
requirement for patients’ consent.
Author details
1Department of General Surgery, Medical University of Graz,
Auenbruggerplatz 29, A-8036 Graz, Austria. 2Institute of Pathology, Medical
University of Graz, Graz, Austria.
Received: 11 May 2016 Accepted: 25 October 2016
References
1. Fernandez-del Castillo C, Adsay NV. Intraductal papillary mucinous
neoplasms of the pancreas. Gastroenterology. 2010;139:708–13.
2. Kloppel G, Solcia E, Longnecker DS, Capellac C, Sobin LH. Histological typing of
tumours of the exocrine pancreas. In: World Health Organization international
classification of tumours. 2nd ed. Berlin: Springer; 1996. p. 11–20.
3. Furukawa T, Kloppel G, VolkanAdsay N, Albores-Saavedra J, Fukushima N, Horii
A, et al. Classification of types of intraductal papillary-mucinous neoplasm of
the pancreas: a consensus study. Virchows Arch. 2005;447(5):794–9.
4. Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, Falconi M, Shimizu M,
et al. International consensus guidelines for management of intraductal
papillary mucinous neoplasms and mucinous cystic neoplasms of the
pancreas. Pancreatology. 2006;6(1-2):17–32.
5. Shi C, Klein AP, Goggins M, Maitra A, Canto M, Ali S, et al. Increased
Prevalence of Precursor Lesions in Familial Pancreatic Cancer Patients. Clin
Cancer Res. 2009;15(24):7737–43.
6. Castellano-Megias VM, Ibarrola-de Andres C, Lopez-Alonso G, Colina-Ruizdelgado
F. Pathological features and diagnosis of intraductal papillary mucinous neoplasm
of the pancreas. World J GastrointestOncol. 2014;6(9):311–24.
7. Tanaka M, Fernandez-del Castillo C, Adsay V, Chari S, Falconi M, Jang JY,
et al. International consensus guidelines 2012 for the management of IPMN
and MCN of the pancreas. Pancreatology. 2012;12(3):183–97.
8. Takaori K. Current understanding of precursors to pancreatic cancer. J
Hepatobiliary Pancreat Surg. 2007;14(3):217–23.
9. Bosman FT, Carneiro F, Hruban RH, Theise ND (Eds.), WHO Classification of
Tumours of the Digestive System., 4th Edition, International Agency for
Research on Cancer, Lyon 2010
10. Luttges J, Zamboni G, Longnecker D, Kloppel G. The immunohistochemical
mucin expression pattern distinguishes different types of intraductal
papillary mucinous neoplasms of the pancreas and determines their
relationship to mucinous noncystic carcinoma and ductal adenocarcinoma.
Am J SurgPathol. 2001;25(7):942–8.
11. Furukawa T, Hatori T, Fujita I, Yamamoto M, Kobayashi M, Ohike N, et al.
Prognostic relevance of morphological types of intraductal papillary
mucinous neoplasms of the pancreas. Gut. 2011;60(4):509–16.
12. Adsay NV, Merati K, Andea A, Sarkar F, Hruban RH, Wilentz RE, et al. The
dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in
the pancreas: differential expression of MUC1 and MUC2 supports the
existence of two separate pathways of carcinogenesis. Mod Pathol. 2002;
15(10):1087–95.
13. Takasu N, Kimura W, Moriya T, Hirai I, Takeshita A, Kamio Y, et al.
Intraductal papillary-mucinous neoplasms of the gastric and intestinal
types may have less malignant potential than the pancreatobiliary type.
Pancreas. 2010;39(5):604–10.
14. Sohn TA, Yeo CJ, Cameron JL, Hruban RH, Fukushima N, Campbell KA, et al.
Intraductal papillary mucinous neoplasms of the pancreas: an updated
experience. Ann Surg. 2004;239(6):788–97. discussion 97-9.
15. D'Angelica M, Brennan MF, Suriawinata AA, Klimstra D, Conlon KC.
Intraductal papillary mucinous neoplasms of the pancreas: an analysis of
clinicopathologic features and outcome. Ann Surg. 2004;239(3):400–8.
16. Crippa S, Fernandez-Del Castillo C, Salvia R, Finkelstein D, Bassi C,
Dominguez I, et al. Mucin-producing neoplasms of the pancreas: an analysis
Marsoner et al. BMC Cancer  (2016) 16:844 Page 13 of 14
of distinguishing clinical and epidemiologic characteristics. Clin
Gastroenterol Hepatol. 2010;8(2):213–9.
17. Dindo D, Demartines N, Clavien PA. Classification of surgical complications:
a new proposal with evaluation in a cohort of 6336 patients and results of a
survey. Ann Surg. 2004;240:205–13.
18. Austrian National cancer registry. http://www.statistik.at/web_de/statistiken/
menschen_und_gesellschaft/gesundheit/krebserkrankungen/
bauchspeicheldruese/index.html
19. Sahora K, Fernandez-del CC. Intraductal papillary mucinous neoplasms.
CurrOpinGastroenterol. 2015;31:424–9.
20. Niedergethmann M, Grutzmann R, Hildenbrand R, Dittert D, Aramin N,
Franz M, et al. Outcome of invasive and noninvasive intraductal papillary-
mucinous neoplasms of the pancreas (IPMN): a 10-year experience. World
J Surg. 2008;32(10):2253–60.
21. Baiocchi GL, Bertagna F, Gheza F, Grazioli L, Calanducci D, Giubbini R, et al.
Searching for indicators of malignancy in pancreatic intraductal papillary
mucinous neoplasms: the value of 18FDG-PET confirmed. Ann SurgOncol.
2012;19(11):3574–80.
22. Marchegiani G, Mino-Kenudson M, Sahora K, Morales-Oyarvide V, Thayer S,
Ferrone C, Warshaw AL, Lillemoe KD, Fernandez-del CC. IPMN Involving the
Main Pancreatic Duct. Biology, epidemiology, and long-term outcomes
following resection. Ann Surg. 2015;261:976–83.
23. Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive
pancreaticoduodenectomies. Ann Surg. 2006;244(1):10–5.
24. Andrén-Sandberg A, Neoptolemos JP. Resection for pancreatic cancer in the
new millenium. Pancreatology. 2002;2(5):431–39.
25. Marsoner K, Kornprat P, Sodeck G, Schagerl J, Langeder R, Csengeri D, Wagner
D, Mischinger HJ, Haybaeck J. Pancreas cancer surgery in octogenarians –
should we or should we not? Anticancer Res. 2016;36(4):1979–84.
26. Shimada K, Sakamoto Y, Sano T, Kosuge T, Hiraoka N. Invasive carcinoma
originating in an intraductal papillary mucinous neoplasm of the pancreas:
a clinicopathologic comparison with a common type of invasive ductal
carcinoma. Pancreas. 2006;32(4):281–7.
27. Brambs HJ, Juchems M. Cystic tumors of the pancreas. Radiologe. 2008;
48(8):740–51.
28. Brambs HJ, Juchems M. Radiologische Diagnostik der intraduktalen papillär
muzinösen Neoplasie. Chirurg. 2012;83(2):116–22.
29. Ogawa H, Itoh S, Ikeda M, Suzuki K, Naganawa S. Intraductal papillary
mucinous neoplasm of the pancreas: assessment of the likelihood of
invasiveness with multisection CT. Radiology. 2008;248(3):876–86.
30. Austrian cancer registry. http://www.statistik.at/web_de/statistiken/
menschen_und_gesellschaft/gesundheit/krebserkrankungen/
krebspraevalenz/index.html
31. Sahora K, Crippa S, Zamboni G, Ferrone C, Warshaw AL, Lillemoe K, Mino-
Kenudson M, Falconi M, Fernandez-del CC. Intraductal papillary mucinous
neoplasms of the pancreas with concurrent pancreatic and periampullary
neoplasms. EJSO. 2016;42:197–204.
32. Kawai M, Uchiyama K, Tani M, Onishi H, Kinoshita H, Ueno M, et al.
Clinicopathological features of malignant intraductal papillary mucinous
tumors of the pancreas: the differential diagnosis from benign entities.
Arch Surg. 2004;139(2):188–92.
33. Goh BK, Tan YM, Thng CH, Cheow PC, Chung YF, Chow PK, et al. How
useful are clinical, biochemical, and cross-sectional imaging features in
predicting potentially malignant or malignant cystic lesions of the
pancreas? Results from a single institution experience with 220 surgically
treated patients. J Am Coll Surg. 2008;206(1):17–27.
34. Wang W, Zhang L, Chen L, Wei J, Sun Q, Xie Q, Zhou X, Zhou D, Huang P,
Yang Q, Xie H, Zhou L, Zheng S. Serum carcinoembryonic antigen and
carbohydrate antigen 19-9 for predicition of malignancy and invasiveness in
intraductal papillary neoplasms: a meta-analysis. Biomed Rep. 2015;3:43–50.
35. Fritz S, Hackert T, Hinz U, Hartwig W, Büchler MR, Werner J. Role of serum
carbohydrate antigen and carcinoembryotic antigen in distinguishing
between benign and invasive intraductal papillary neoplasms of the
pancreas. Br J Surg. 2011;98:104–10.
36. Sahora K, Mino-Kenudson M, Brugge W, Thayer SP, Cr F, Sahani D, Pitman
MB, Warshaw AL, Lillemoe KD, Fernandez-del Castillo CF. Branch duct
intraductal papillary mucinous neoplasms: does cyst size change the tip of
the scale? A critical analysis of the revised international consensus
guidelines in a large single-institutional series. Ann Surg. 2013;258:466–75.
37. Brugge WR, Lauwers GY, Sahani D, Fernandez-del Castillo C, Warshaw AL.
Cystic neoplasms of the pancreas. N Engl J Med. 2004;16;351(12):1218–26.
38. Farrell JJ. Prevalence, diagnosis and management of pancreatic cystic
neoplasms: current status and future directions. Gut Liver. 2015;9(5):571–89.
39. Saito M, Ishihara T, Tada M, Tsuyuguchi T, Mikata R, Sakai Y, Tawada K,
Sugiyama H, Kurosawa J, Otuska M, Uchida Y, Uchiyama K, Miyazaki M,
Yokosuka O. Use of F-18 fluorodeoxyglucose positron emission tomography
with dual-phase imaging to identify intraductal papillary mucinous
neoplasm. ClinGastroenterolHeatol. 2013;11(2):181–6.
40. Rodriguez JR, Salvia R, Crippa S, Warshaw AL, Bassi C, Falconi M, et al. Branch-
duct intraductal papillary mucinous neoplasms: observations in 145 patients
who underwent resection. Gastroenterology. 2007;133(1):72–9. quiz 309-10.
41. Mimura T, Masuda A, Matsumoto I, Shiomi H, Yoshida S, Sugimoto M,
Sanuki T, Yoshida M, Fujita T, Kutsumi H, Ku Y, Azuma T. Predictors of
malignant intraductal papillary mucinous neoplasm of the pancreas. J
ClinGastroenterol. 2010;44(9):224–9.
42. Austrian cancer registry. http://www.statistik.at/web_de/statistiken/
menschen_und_gesellschaft/gesundheit/todesursachen/todesursachen_
ausgewaehlte/index.html
43. He J, Cameron JL, Ahuja N, Makary MA, Hirose K, Choti MA, Schulick RD,
Hruban RH, Pawlik TM, Wolfgang CL. Is it necessary to follow patients after
resection of a benign pancreatic intraductal papillary mucinous neoplasm?
J Am CollSurg. 2013;216:657–65.
44. Xourafas D, Tavakkoli A, Clancy T, Ashley SW. Noninvasive intraductal
papillary mucinous neoplasms and mucinous cystic neoplasms: Recurrence
rates and postoperative imaging follow-up. Surgery. 2015;157:473–83.
45. Salvia R, Fernandez-del Castillo C, Bassi C, Thayer SP, Falconi M, Mantovani
W, et al. Main-duct intraductal papillary mucinous neoplasms of the
pancreas: clinical predictors of malignancy and long-term survival following
resection. Ann Surg. 2004;239(5):678–85. discussion 85-7.
46. Minu-Kenudson M, Fernandez-del Castillo C, Baba Y, Valsangkar NP, Liss AS, Hsu
M, Correa-Gallego C, Ingkakul T, Perez Johnston R, Turner BG, Androutsopoulos
V, Deshpande V, McGrath D, Sahani DV, Brugge WR, Ogino S, Pitman MB,
Warshaw AL, Thayer SP. Prognosis of invasive intraductal papillary mucinous
neoplasm depends on histological and precursor epithelial subtypes. Gut. 2011;
60(12):1712–20.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Marsoner et al. BMC Cancer  (2016) 16:844 Page 14 of 14
